337 related articles for article (PubMed ID: 25795719)
1. Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.
Araki D; Othus M; Walter RB; Sandhu V; Sandmaier BM; Becker PS; Appelbaum FR; Estey EH
Haematologica; 2015 Jul; 100(7):e254-6. PubMed ID: 25795719
[No Abstract] [Full Text] [Related]
2. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
3. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic cell transplantation for adults with acute myeloid leukemia with minimal residual disease.
Appelbaum FR
Best Pract Res Clin Haematol; 2015; 28(2-3):133-40. PubMed ID: 26590770
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
Damiani D; Tiribelli M; Geromin A; Michelutti A; Cavallin M; Sperotto A; Fanin R
Am J Hematol; 2015 Sep; 90(9):784-9. PubMed ID: 26059733
[TBL] [Abstract][Full Text] [Related]
6. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.
Sengsayadeth S; Savani BN; Blaise D; Malard F; Nagler A; Mohty M
Haematologica; 2015 Jul; 100(7):859-69. PubMed ID: 26130513
[TBL] [Abstract][Full Text] [Related]
7. Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
Lim SJ; Lim MJ; Raptis A; Hou JZ; Farah R; Marks SM; Im A; Dorritie K; Sehgal A; Agha M; Felgar R; Lim SH
Am J Hematol; 2015 Aug; 90(8):715-8. PubMed ID: 26010177
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
9. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
[TBL] [Abstract][Full Text] [Related]
10. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
11. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
[TBL] [Abstract][Full Text] [Related]
12. Higher busulfan dose intensity appears to improve leukemia-free and overall survival in AML allografted in CR2: An analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Kharfan-Dabaja MA; Labopin M; Bazarbachi A; Socie G; Kroeger N; Blaise D; Veelken H; Bermudez A; Or R; Lioure B; Beelen D; Fegueux N; Hamladji RM; Nagler A; Mohty M
Leuk Res; 2015 Sep; 39(9):933-7. PubMed ID: 26003666
[TBL] [Abstract][Full Text] [Related]
13. Benefit of allogeneic transplantation in patients age ≥ 60 years with acute myeloid leukemia is limited to those in first complete remission at time of transplant.
Michelis FV; Messner HA; Atenafu EG; Kim DD; Kuruvilla J; Lipton JH; Uhm J; Loach D; Gupta V
Biol Blood Marrow Transplant; 2014 Apr; 20(4):474-9. PubMed ID: 24345422
[TBL] [Abstract][Full Text] [Related]
14. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
15. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
16. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
Khawaja MR; Perkins SM; Schwartz JE; Robertson MJ; Kiel PJ; Sayar H; Cox EA; Vance GH; Farag SS; Cripe LD; Nelson RP
Am J Hematol; 2015 Feb; 90(2):97-9. PubMed ID: 25345651
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
20. Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.
Walter RB; Sandmaier BM; Storer BE; Godwin CD; Buckley SA; Pagel JM; Sorror ML; Deeg HJ; Storb R; Appelbaum FR
Biol Blood Marrow Transplant; 2015 Feb; 21(2):373-8. PubMed ID: 25278455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
